GlassScriptPhysician profile
Henry G Luu
NPI 1306864947
$4,666.28
in general payments reported to CMS, 2019-2025
20 companies · $1,017 in 2025
The $1,017 reported for 2025 was more than what 89% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
See the full distribution for Addiction Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $80.61 · 2021: $671 · 2022: $800 · 2023: $1,090 · 2024: $784 · 2025: $1,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,891.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $828.70 | 2023-2025 | Brixadi |
| Novo Nordisk INC | $807.33 | 2021-2025 | Ozempic, Rybelsus |
| Indivior INC. | $638.96 | 2021-2025 | Sublocade |
| Abbvie INC. | $636.30 | 2020-2025 | |
| Corium, LLC | $588.44 | 2022-2025 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $361.28 | 2022-2023 | Breztri, Farxiga |
| Gilead Sciences, INC. | $177.09 | 2021-2023 | |
| Lilly USA, LLC | $115.20 | 2023 | Mounjaro |
| Adlon Therapeutics L.P. | $97.71 | 2019-2021 | |
| Orexo US, INC. | $94.45 | 2019-2021 | |
| Alkermes, INC. | $91.60 | 2019-2024 | Vivitrol |
| Boston Scientific Corporation | $64.23 | 2019 | |
| Glaxosmithkline, LLC. | $36.81 | 2023 | Arexvy, Shingrix |
| Janssen Biotech, INC. | $26.32 | 2022 | |
| Polarityte, INC. | $22.14 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $18.02 | 2024 | Relexxii |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.01 | 2024 | Xifaxan |
| Amarin Pharma, INC. | $17.74 | 2022 | |
| Mdd US Operations, LLC | $14.16 | 2019 | |
| Shire North American Group INC | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Luu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.